Testing Cilostazol and Ginkgo Leaf Extract for Memory in Older Adults With Diabetes
Tests cilostazol with ginkgo leaf extract against placebo in older adults with type 2 diabetes.
Key facts
- Who runs it
- Seoul National University Bundang Hospital
- Where
- Seongnam-si, South KoreaSee the site
- Trial code
- Registry title
- Cilostazol-Ginkgo for Cognitive Function in Elderly Diabetes
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 80 people, planned
- Started
- 1 Jan 2025
- Expected to end
- 30 Jun 2027
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Cilostazol / Ginko Leaf Dried Ext.
- Placebo
- Record updated
- 25 May 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 60 or older with type 2 diabetes and mildly lowered memory and thinking test scores. It tests cilostazol with ginkgo leaf extract.
- Age
- 60 years or older
- Sex
- All sexes can join.
- Disease stage
- Type 2 diabetes with a Mini-Mental State Examination (MMSE) score between 24 and 28 within the past 3 months.
- Earlier treatment
- Cannot have taken medicines that may affect thinking and memory within 3 months before screening.
Main reasons for not taking part
- Type 1 diabetes, diabetic ketoacidosis, or diabetic coma or precoma
- Poorly controlled blood sugar (HbA1c above 10.0% (86 mmol/mol))
- MMSE score below 24, or a diagnosis of dementia such as Alzheimer's disease
- Needing other blood-thinning or antiplatelet medicine
- Severe depression, or alcohol or drug abuse within 1 year before screening
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- Patients diagnosed with type 2 diabetes mellitus
- Adults aged 60 years or older
- Patients with a Mini-Mental State Examination (MMSE) score between 24 and 28 within the past 3 months
Who cannot take part
- Patients requiring antiplatelet or anticoagulant therapy other than the investigational product
- Patients with a history of alcohol or drug abuse within 1 year prior to screening
- Patients with a history of taking medications that may affect cognitive function within 3 months prior to screening
- Patients with type 1 diabetes mellitus, diabetic ketoacidosis, or diabetic coma or precoma
- Patients diagnosed with dementia (e.g., Alzheimer's disease)
- Patients with suspected cognitive impairment due to other causes
- Patients with severe infections, recent surgery (perioperative status), or major trauma
- Patients with pituitary or adrenal insufficiency
- Patients with other medical conditions requiring hospitalization
- Patients with poorly controlled blood glucose (HbA1c > 10.0%)
- Patients with an MMSE score below 24
- Patients with thyroid dysfunction requiring treatment (i.e., abnormal TSH levels)
- Patients with severe depression
- Patients deemed by the investigator to be otherwise unsuitable for study participation
Where in South Korea
- Seoul National University Bundang HospitalSeongnam-si, South KoreaContact: Soo Lim Dr., MD PhDTaking people
About the trial
What the trial wants to find out
This exploratory pilot study aims to evaluate the cognitive improvement effects of combination therapy with cilostazol (200 mg) and ginkgo biloba extract (160 mg) in elderly patients with type 2 diabetes mellitus. Both agents have demonstrated potential cognitive benefits through mechanisms such as enhanced cerebral blood flow, anti-inflammatory activity, and neuroprotection. Given the increased risk of cognitive decline and dementia in patients with type 2 diabetes, and the need for preventive strategies, this study will investigate whether the combination therapy can prevent or mitigate cognitive deterioration. Findings from this study may provide foundational data for the future development of therapeutic interventions targeting cognitive impairment in patients with diabetes.
The 2 groups in the trial
- Cilostazol & Ginko Leaf Dried Ext.Treatment being tested
Renexin CR tab (cilostazol 200mg / Ginko Leaf Dried Ext. 160mg)
- PlaceboPlacebo, for comparison
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Impact of Cilostazol and Ginkgo Leaf Extract on Cognitive Function in Elderly Patients With Type 2 Diabetes
- Plain-language title
- Testing Cilostazol and Ginkgo Leaf Extract for Memory in Older Adults With DiabetesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 25 May 2025